Sarah, a 34-year-old marketing assistant from Manchester, first felt her heart race at her desk in early 2024. Within weeks, the palpitations came daily, accompanied by a sense of impending doom that left her unable to leave the house. Her GP diagnosed generalised anxiety disorder and prescribed lorazepam, a benzodiazepine, for acute episodes. Sarah asked about therapy. The GP referred her to NHS Talking Therapies and warned the wait could be long. Fourteen months later, Sarah had heard nothing. By then, she was buying diazepam online from unregulated sources, unable to stop without support.

Sarah's story is not unusual. Across the UK, general practitioners face a daily dilemma: a patient in distress, a ten-minute appointment slot, and a therapy system that cannot keep up. The result is a prescription pad solution to a structural problem. Benzodiazepine prescribing in England rose roughly 8% in 2025 alone, according to NHS Business Services Authority data reported by the British Medical Journal. Meanwhile, waits for cognitive behavioural therapy (CBT) in some areas exceed two years. This feature examines how a single clinical encounter concentrates a much larger failure, and what might change it.

A Two-Year Wait and a Ten-Minute Prescription

The gap between what patients need and what GPs can offer is stark. A 2025 survey by the Royal College of General Practitioners found that nearly two-thirds of GPs reported a significant increase in patients seeking help for anxiety compared to five years earlier. The same survey found that 78% of GPs felt unable to refer patients to timely talking therapies. In many parts of England, NHS Talking Therapies (formerly IAPT) reports average waits of 18 weeks for initial assessment. For specialist CBT for severe anxiety disorders, waits of 18 to 24 months are common.

In the same ten-minute consultation, a GP can write a prescription for a benzodiazepine—lorazepam, diazepam, or alprazolam—that the patient can fill within an hour. The drug works quickly, dampening the amygdala's fear response and offering immediate relief. For a patient in crisis, that feels like help. For the GP, it feels like the only available tool. The prescription is not a clinical preference; it is a workaround for a missing system.

The tension is not lost on clinicians. Dr. Eleanor Cross, a GP in Birmingham, told Pulse magazine in 2025: “I know benzodiazepines are not ideal long-term. But when I have a patient hyperventilating in my room, and the therapy waitlist is two years, what am I supposed to do? Send them home with a leaflet?” The question is rhetorical, but it captures a daily reality repeated in thousands of practices.

Patients often leave satisfied—symptoms controlled, a plan in hand. But the satisfaction is short-lived. Benzodiazepines are intended for short-term use, typically no more than two to four weeks. Beyond that, tolerance develops, and dependence sets in. The prescription that solved today's crisis plants the seed for tomorrow's chronic problem.

The Benzodiazepine Treadmill: Quick Relief, Long Cost

Benzodiazepines are among the most effective drugs for acute anxiety. They enhance the effect of GABA, the brain's primary inhibitory neurotransmitter, producing rapid sedation and anxiolysis. For a patient in the midst of a panic attack, they are transformative. But the same pharmacology that makes them effective makes them addictive. With regular use, the brain downregulates GABA receptors, requiring higher doses to achieve the same effect. Withdrawal can trigger rebound anxiety, insomnia, and seizures.

The UK prescribing data is concerning. In 2025, approximately 8.5 million benzodiazepine prescriptions were dispensed in England, a rise of roughly 8% from the previous year, according to NHS Business Services Authority figures. A 2024 analysis in the British Journal of General Practice found that nearly one in five new benzodiazepine prescriptions were followed by repeat prescriptions for more than four weeks, exceeding guideline limits. Long-term use is linked to falls, cognitive decline, and increased mortality in older adults.

GPs feel the pressure. In a 2025 survey by Pulse, 44% of GPs said they had prescribed benzodiazepines against their clinical judgment because they had no alternative to offer. Patients often expect a prescription, and refusing can feel like abandoning them. “You’re caught between guidelines and reality,” one GP said. The guidelines recommend CBT and SSRIs as first-line treatment. But CBT is unavailable, and SSRIs take weeks to work and can worsen anxiety initially.

The treadmill is hard to escape. Once a patient has been on benzodiazepines for months, tapering requires time, support, and often specialist input—resources that are scarce. A 2023 Cochrane review found that slow tapering combined with psychological support improves success rates, but such support is rarely available in primary care. The system that pushed the prescription is the same system that cannot help the patient stop.

Therapy Waitlists as a Structural Barrier

NHS Talking Therapies, launched in 2008 as IAPT, was designed to improve access to evidence-based psychological therapies. In many ways, it succeeded: over 1.2 million people entered treatment in 2024–25, and recovery rates hover around 50%. But demand has outpaced capacity. The average wait for a first appointment now stands at 18 weeks, according to NHS England data. For some services, waits exceed 12 months.

Specialist CBT for anxiety disorders—such as panic disorder, social anxiety, and generalised anxiety—requires therapists with specific training. These are in short supply. A 2025 report by the Centre for Mental Health estimated that the NHS is short of roughly 2,500 CBT therapists nationally. In rural areas, the shortage is acute. Some patients travel over an hour for appointments, if they can get one at all.

Private therapy offers a faster route but at a cost. A typical CBT session costs between £50 and £80, and a course of treatment often requires 12 to 20 sessions. For a patient on a median UK salary of £35,000, that is a significant outlay. Many cannot afford it. The result is a two-tier system: those with means access timely therapy, while others rely on pills or nothing.

Waitlist length itself predicts worse outcomes. A 2022 study in Psychological Medicine found that patients who waited more than six months for CBT had significantly higher dropout rates and lower recovery rates than those seen within four weeks. The longer people wait, the more their condition worsens, and the harder it becomes to treat. The waitlist is not neutral—it is an active harm.

Patient Experience: Sarah's Story

Sarah’s panic attacks began in early 2024, triggered by work stress and the lingering effects of the pandemic. Her GP, Dr. Singh, prescribed lorazepam 1 mg for acute episodes and referred her to the local NHS Talking Therapies service. “He was kind and listened,” Sarah recalls. “But he said the wait might be up to a year. I thought that can’t be right.” She was given a leaflet on breathing exercises and a prescription for 14 tablets.

The lorazepam worked. Within 20 minutes of taking a tablet, the racing heart stopped, and the fear subsided. Sarah used them sparingly at first—once a week, then twice. By the third month, she was taking one almost daily. She called the therapy service every few weeks. Each time, she was told her referral was on the list and she would be contacted when an appointment became available. After six months, she stopped calling.

At month 14, Sarah had not heard from the service. By then, she was buying diazepam online from a website based in India. The tablets arrived in unmarked packets, and she had no idea of the dose or purity. She was taking roughly 20 mg a day, far above the recommended maximum. When she tried to stop, she experienced severe rebound anxiety, insomnia, and tremors. She confided in her GP, who referred her to a specialist addiction service. The wait for that was six months.

Sarah’s story is one of many. A 2025 investigation by The Guardian found that online sales of benzodiazepines had surged, with some websites selling thousands of tablets per month. Patients who cannot access therapy or afford private care turn to unregulated sources, risking overdose and contamination. The system that failed to provide therapy does not track these patients until they present in crisis.

Inequity Across the Wealth Gradient

Wealth is a powerful determinant of mental health care. A patient in a high-income bracket can see a private CBT therapist within a week, pay £70 per session, and complete a course in three to four months. A patient on universal credit may wait two years for the same therapy on the NHS, or never get it at all. The gap is not just about speed; it is about outcomes. A 2024 study in The Lancet Psychiatry found that patients from the most deprived quintile had 40% lower recovery rates from anxiety treatment than those from the least deprived quintile, even after adjusting for symptom severity at intake.

Private benzodiazepine prescriptions are easier to obtain for those who can pay. Online private GP services offer same-day consultations for around £50, and benzodiazepines are sometimes prescribed after a brief video call. A 2025 undercover investigation by BBC News found that several private telehealth platforms prescribed benzodiazepines without adequate assessment or follow-up. The affluent can access quick pills; the poor wait for therapy that never comes.

Digital CBT apps have been proposed as a scalable solution. Apps like Silvercloud, Iesō, and Minddistrict are used by some NHS services to supplement face-to-face therapy. Evidence is mixed. A 2024 meta-analysis in JAMA Psychiatry found that digital CBT reduced anxiety symptoms moderately compared to waitlist controls, but dropout rates were high—often above 40%—and effects waned over time. For patients with severe anxiety, digital alone is rarely sufficient.

The wealth gradient extends to dependence. A 2023 study in Addiction found that long-term benzodiazepine use was more common in deprived areas, where access to alternatives was lowest. The same communities that face longer therapy waits also face higher prescribing rates and worse outcomes. The inequality is not incidental; it is built into the system.

Similar patterns exist in other countries. In the United States, where therapy is often limited by insurance networks, benzodiazepine prescribing is higher among Medicaid patients than privately insured patients, according to a 2024 CDC report. In Australia, a 2025 analysis found that patients in rural areas were twice as likely to receive benzodiazepines and half as likely to receive CBT as urban patients. The dynamic is global: where therapy is scarce, pills fill the gap.

What Would Help: Policy and Practice Fixes

Expanding NHS Talking Therapies capacity is the most direct fix. The 2024 NHS Long Term Plan committed to increasing access, but funding has not kept pace. The Centre for Mental Health estimates that an additional £500 million per year would reduce waits to under four weeks nationwide. That sum is roughly 0.3% of the NHS budget—a small investment relative to the costs of untreated anxiety and benzodiazepine dependence.

Training GPs in brief anxiety interventions could reduce reliance on pills. The National Institute for Health and Care Excellence (NICE) recommends guided self-help based on CBT principles as a first step. Brief interventions—typically 6 to 8 sessions of low-intensity CBT delivered by a mental health practitioner in primary care—have shown promise. A 2025 trial in The Lancet found that such interventions reduced anxiety scores by 40% and halved benzodiazepine prescribing at 12 months.

Prescribing guidelines for benzodiazepines exist but are poorly followed. NICE recommends that benzodiazepines be used for no more than four weeks, and only when other treatments are ineffective or unavailable. A 2023 audit in the British Journal of General Practice found that fewer than 30% of repeat prescriptions were accompanied by a documented tapering plan. Implementing electronic alerts in GP systems that flag repeat prescriptions and prompt tapering discussions could help.

Community mental health hubs, where patients can access therapy, social support, and medication management in one place, are a model gaining traction. Pilot programmes in Liverpool and Bristol have shown reductions in emergency department visits and improved patient satisfaction. A 2025 evaluation by the King’s Fund recommended scaling these hubs nationally, with a focus on deprived areas where need is highest.

National targets to reduce therapy waitlists below four weeks would set a clear standard. The current target of 18 weeks for NHS Talking Therapies is not ambitious enough; many patients deteriorate in that time. A four-week target would require significant investment but would align with clinical evidence on optimal timing. Without such targets, the gap between policy and practice will persist.

Some argue that prescribing benzodiazepines is not always a failure. For short-term crises, they are appropriate. The problem is not the drug itself but the system that forces it to be used as a long-term solution. A balanced approach would preserve access for acute use while building infrastructure to provide alternatives for the majority of patients who need more than a pill.

The Real Cost of the Status Quo

The financial costs of the current approach are substantial. Treating benzodiazepine dependence costs the NHS an estimated £200 million per year, according to a 2024 report by Public Health England, including hospital admissions for falls, overdose, and withdrawal complications. Lost productivity from untreated anxiety is far larger: the Centre for Mental Health estimates it at £34 billion annually in England alone, through absenteeism, presenteeism, and disability benefits.

Human costs are harder to quantify but more profound. Patients like Sarah lose years of their lives to avoidable disability. They miss work, withdraw from relationships, and develop chronic health problems. The benzodiazepine that was meant to help becomes a trap. The therapy that could have helped never arrives. The system that created the problem is the same system that cannot fix it.

Reasonable people disagree on solutions. Some argue for stricter prescribing controls to reduce benzodiazepine use, but that risks leaving patients without any support. Others advocate for massive therapy expansion, but funding is limited and therapists cannot be trained overnight. Digital solutions offer scale but not depth. There is no single fix.

What is clear is that the status quo is a political choice, not a clinical inevitability. Every year that therapy waitlists remain at two years, every month that a GP writes a prescription because no alternative exists, is a decision—made implicitly—to accept the current distribution of suffering. The question is not whether we can do better. It is whether we will.

This article is for informational purposes only and does not constitute personalised medical advice. If you are experiencing anxiety or benzodiazepine dependence, consult a healthcare professional. For immediate support, contact Samaritans at 116 123 or NHS 111.